

Acute Limb Ischemia - An Urgent Call for Enhanced Care

Acute limb ischemia (ALI) is a severe and sudden condition characterized by a decrease in limb perfusion, which can potentially threaten the viability of the limb. It is considered a medical emergency and necessitates immediate medical intervention.¹ The condition arises when the blood flow to a limb is significantly reduced or stopped, generally due to a blockage in the arteries. This blockage is commonly caused by a blood clot (thrombus) that has formed in the artery itself or travelled from another part of the body (embolism). Less frequently, ALI can be caused by trauma, infection, or the narrowing of the arteries due to atherosclerosis.² Despite the gravity of this condition, the management of ALI is fraught with significant challenges.

Timely diagnosis and treatment are indeed critical in managing Acute Limb Ischemia (ALI). The symptoms of ALI, can be nonspecific and may overlap with several other conditions. This can lead to diagnostic confusion, particularly in patients with pre-existing peripheral arterial disease (PAD), where symptoms might be attributed to their chronic disease instead of an acute event.² The “time-is-tissue” concept underscores the urgency of immediate intervention to prevent irreversible tissue damage. This principle is well recognized in conditions such as stroke and myocardial infarction. However, in the context of ALI, this concept is not as widely recognized, contributing to treatment delays.³ Furthermore, Recognizing Acute Limb Ischemia (ALI) in younger COVID-19 patients with minimal or no atherosclerosis can be difficult. The severe inflammatory response in COVID-19 can trigger a hypercoagulable state, increasing the risk of thrombotic events such as ALI. However, in severe cases, the systemic and respiratory symptoms may overshadow ALI symptoms, causing

misattribution to other complications and resulting in diagnostic and treatment delays.^{4,5}

To improve the outcomes of patients with ALI, it is crucial to enhance the awareness about this condition among healthcare professionals and the general public, stressing the “time-is-tissue” principle and the need for immediate medical attention if ALI is suspected.

Enhancing awareness about Acute Limb Ischemia (ALI) among healthcare professionals and the public is indeed vital to improving patient outcomes. This is particularly important given the nonspecific nature of ALI symptoms and the necessity of immediate treatment to prevent irreversible tissue damage. The “six P’s” of ALI - Pain, Pallor (pale skin color), Pulselessness, Paralysis, Paresthesia (numbness or tingling), and Perishing cold - should be widely recognized and understood by healthcare professionals. Continuing education and frequent training sessions can help ensure that these symptoms are promptly recognized and correctly interpreted.³

Risk stratification in Acute Limb Ischemia (ALI) involves determining the severity of the disease and potential patient outcomes. This information can then guide treatment decisions and clinical management. The Rutherford classification system is commonly used in ALI risk stratification.⁶ This system classifies ALI into three categories:

- Class I: Viable - Not immediately threatened
- Class IIa: Marginally threatened - Salvageable if promptly treated
- Class IIb: Immediately threatened - Requires immediate revascularization
- Class III: Irreversible - Major tissue loss or

permanent nerve damage inevitable.

While the Rutherford classification has been widely used and is helpful, it may not fully capture the complexity of patient presentations and outcomes in ALI. For example, it does not account for patient comorbidities, which can significantly impact prognosis and treatment planning. Furthermore, the system's criteria, particularly for distinguishing between classes IIa and IIb, can be somewhat subjective and may lead to inconsistencies in classification.⁷

Given these limitations, there is a need for more comprehensive risk stratification models. These could potentially incorporate a wider range of variables, such as patient comorbidities, the extent of ischemia, biochemical markers, and the presence of infection or sepsis. The development of these tools will require further research, including large-scale, multi-center studies to validate their accuracy and usefulness in clinical practice. The ultimate goal should be to develop a model that accurately identifies high-risk patients, guides treatment decisions, and predicts outcomes, thereby improving the care and prognosis of patients with ALI.

Balancing the stress of the procedure, the risk of staff infection, resource use, and the higher mortality risk associated with conservative treatment complicates the choice between surgical thrombectomy, catheter-directed thrombolysis, or primary amputation for acute limb ischemia (ALI). This highlights the need for robust clinical trials to inform guidelines on the optimal first-line treatment.^{4,6}

Determining the right anticoagulation level to prevent thrombosis without causing bleeding events is a major challenge.⁴

Insufficient data exists for innovative ALI treatments like hybrid procedures, ultrasound-accelerated thrombolysis, heated recombinant tissue plasminogen activator, or novel endovascular thrombectomy systems. Traditional approaches, catheter-driven thrombolysis and surgical re-

vascularization, show similar limb salvage rates but carry different risks. Catheter-driven thrombolysis has a higher risk of major vascular events and bleeding, complicating the selection of the safest, most effective treatment.⁸

Reperfusion injury, which occurs when blood flow resumes in ischemic tissues, poses a significant challenge in managing Acute Limb Ischemia (ALI). This event can exacerbate tissue damage and induce systemic inflammatory responses leading to multi-organ dysfunction.⁹ Various management strategies such as antioxidants, anti-inflammatory drugs, and ischemic conditioning techniques are being explored, but their full safety and efficacy profiles need more research.¹⁰ The role of patient-specific factors in reperfusion injury further complicates ALI management, necessitating ongoing research and clinical attention.¹¹

The long-term management of Acute Limb Ischemia (ALI) is challenging, particularly in assessing outcomes like quality of life, pain, and functional status. These outcomes, although critical, are often under-investigated.³ Chronic pain and reduced functional status can impact a patient's daily life significantly, while compromised quality of life can result from physical impairment and psychological distress. More research is necessary to evaluate the effectiveness of current ALI treatment strategies and to develop interventions focused on these long-term outcomes. Potential strategies may include physical rehabilitation, pain management, psychological support, and specialized ongoing medical care.

In conclusion, considerable progress has been achieved in Acute Limb Ischemia (ALI) management, yet perfection is distant. Key areas requiring focus include timely diagnosis to prevent irreversible tissue damage, refining risk stratification integrating patient factors, ischemia extent, and biochemical markers for better treatment decisions. Treatment optimization demands rigorous research balancing effectiveness, safety, and resource use, including exploration of innovative ALI treatments. Minimizing

reperfusion injury and understanding its damaging effects is vital. Long-term care requires improved pain management, functional status preservation, and quality of life enhancement.

In the ALI battle, where every minute and life matters, these challenges must be met.

Dr. Saeed Abdallah Alghamdi

Consultant vascular surgeon

Bisha – Saudi Arabia

References:

- Olin JW, et al. Peripheral Artery Disease: Evolving Role of Exercise, Medical Therapy, and Endovascular Options. *J Am Coll Cardiol.* 2016 Mar 22;67(11):1338-57. doi: 10.1016/j.jacc.2015.12.049. PMID: 26988957.
- Eliason JL, et al. A national and single institutional experience in the contemporary treatment of acute lower extremity ischemia. *Ann Surg.* 2003 Sep;238(3):382-9; discussion 389-90. doi: 10.1097/01.sla.0000086663.49670.d1. PMID: 14501504; PMCID: PMC1422711.
- Baril, D. T. Acute Limb Ischemia. *Rutherford's Vascular Surgery and Endovascular Therapy* (2017).
- Galyfos G, et al, Theodoropoulos C, Michalopoulou V, Sigala F, Filis K. Acute limb ischemia among patients with COVID-19 infection. *J Vasc Surg.* 2022 Jan;75(1):326-342. doi: 10.1016/j.jvs.2021.07.222. Epub 2021 Aug 12. PMID: 34390791; PMCID: PMC8358086.
- Bikdeli B, et al; COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. *J Am Coll Cardiol.* 2020 Jun 16;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17. PMID: 32311448; PMCID: PMC7164881.
- Rutherford RB, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. *J Vasc Surg.* 1997 Sep;26(3):517-38. doi: 10.1016/s0741-5214(97)70045-4. Erratum in: *J Vasc Surg* 2001 Apr;33(4):805. PMID: 9308598.
- Björck, M., Earnshaw, J.J., Acosta, S., Bastos Gonçalves, F., Cochenec, F., Debus, E.S., ... & Menyhei, G. (2018). Editor's Choice – European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia. *Eur J Vasc Endovasc Surg.* 2020 Feb;59(2):173-218. doi: 10.1016/j.ejvs.2019.09.006. Epub 2019 Dec 31. PMID: 31899099.
- Veenstra EB, et al. A systematic review and meta-analysis of endovascular and surgical revascularization techniques in acute limb ischemia. *J Vasc Surg.* 2020 Feb;71(2):654-668. e3. doi: 10.1016/j.jvs.2019.05.031. Epub 2019 Jul 26. PMID: 31353270.
- Eltzschig HK, Eckle T. Ischemia and reperfusion--from mechanism to translation. *Nat Med.* 2011 Nov 7;17(11):1391-401. doi: 10.1038/nm.2507. PMID: 22064429; PMCID: PMC3886192.
- Hausenloy DJ, Yellon DM. Ischaemic conditioning and reperfusion injury. *Nat Rev Cardiol.* 2016 Apr;13(4):193-209. doi: 10.1038/nrcardio.2016.5. Epub 2016 Feb 4. PMID: 26843289.
- Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Ischemia/Reperfusion. *Compr Physiol.* 2016 Dec 6;7(1):113-170. doi: 10.1002/cphy.c160006. PMID: 28135002; PMCID: PMC5648017.